WaveMan
WaveMan · Company
ANAB · Anaptysbio, Inc
> Search tickers & screens ⌘K
LIVE
← All companies

ANAB Anaptysbio (ANAB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001370053
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
119
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $90.2K priced

What the filings say about ANAB

Insiders, 180 days
-$249.4K net sold
1 seller · 100% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$249.4K
1 notice

Anaptysbio insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ANAPTYSBIO, INC insiders sold a net $249.4K of stock across 96 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
RENTON HOLLINGS
Director
SELL
2026-10-02 SECtraded 2026-10-01
5,000
$249.4K
+0.9%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Aug 8, 2025.
  • The trade is 45.5% of the 10,995 shares held after it.
  • No other insider sold within 30 days.
  • 119 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RENTON HOLLINGS sold about $249.4K of ANAB under a 10b5-1 plan on Oct 1, 2026; 119 funds added in the latest 13F quarter.
Schmid John P.
Director
SELL
2026-04-01 SECtraded 2026-03-30
12,596
$701.7K
+29.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 31.8% of the 39,671 shares held after it.
  • 1 other insider sold within 30 days.
  • 119 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schmid John P. sold about $701.7K of ANAB on Mar 30, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 119 funds added in the latest 13F quarter.
Schmid John P.
Director
SELL
2026-04-01 SECtraded 2026-03-30
7,527
$426.8K
+29.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 23.4% of the 32,144 shares held after it.
  • 1 other insider sold within 30 days.
  • 119 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schmid John P. sold about $426.8K of ANAB on Mar 30, 2026; 1 other insider sold within 30 days and 119 funds added in the latest 13F quarter.
Schmid John P.
Director
SELL
2026-04-01 SECtraded 2026-03-30
522
$30.0K
+29.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 1.7% of the 31,622 shares held after it.
  • 1 other insider sold within 30 days.
  • 119 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Schmid John P. sold about $30.0K of ANAB on Mar 30, 2026; 1 other insider sold within 30 days and 119 funds added in the latest 13F quarter.
Faga Daniel
President, CEO
SELL
2026-03-27 SEC
100
$6.6K
+34.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jan 8, 2026.
  • The trade is 0.0% of the 495,965 shares held after it.
  • 1 other insider sold within 30 days.
  • 119 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, CEO Faga Daniel sold about $6.6K of ANAB on Mar 27, 2026; 1 other insider sold within 30 days and 119 funds added in the latest 13F quarter.
96 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 91 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$249.4K over 180 days
-$249.4K over 90 days
more than 51% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
119 funds bought in last quarter
more than 75% of Pharma & Biotech
Revenue
+157.0% year over year
more than 88% of Pharma & Biotech
Margin
-5.6% net margin
more than 68% of Pharma & Biotech
Buybacks
$68.6M repurchased, FY to 2025-12-31
more than 61% of Pharma & Biotech
Short interest
25.6% of the float short (float per yahoo 2026-10-26) · 8.2 days to cover · settled 2026-09-30
more than 91% of Pharma & Biotech
What changed in the last 30 days
Oct 2Director RENTON HOLLINGS sold $249.4K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Director HOLLINGS C RENTON filed to sell $249.4K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ANAB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+119.0%12M
-3%+68%+138%+208%2025-102025-122026-022026-042026-062026-082026-10 2026-03-30 · Schmid John P. sold $701.7K2026-01-05 · Faga Daniel sold $662.3K2026-01-08 · Faga Daniel sold $638.5K2026-02-11 · LOUMEAU ERIC J sold $540.0K2025-12-22 · LOUMEAU ERIC J sold $510.0K2025-12-22 · MULROY DENNIS sold $500.0K2025-12-17 · LOUMEAU ERIC J sold $460.0K2026-01-15 · Marquet Magda sold $447.0K2026-03-30 · Schmid John P. sold $426.8K2025-12-16 · MULROY DENNIS sold $417.9K2026-01-07 · Faga Daniel sold $415.1K2025-12-16 · LOUMEAU ERIC J sold $371.1K2025-12-16 · MULROY DENNIS sold $287.5K2026-10-01 · RENTON HOLLINGS sold $249.4K2026-01-07 · LOUMEAU ERIC J sold $239.7K2026-03-27 · Faga Daniel sold $214.7K2026-03-27 · Faga Daniel sold $202.5K2026-03-27 · Faga Daniel sold $198.1K2025-12-23 · Ware J. Anthony sold $193.4K2025-12-16 · LOUMEAU ERIC J sold $189.8K2026-01-05 · Lizzul Paul F. sold $182.5K2026-03-27 · Faga Daniel sold $164.2K2026-01-08 · Lizzul Paul F. sold $163.2K2026-03-27 · Faga Daniel sold $148.8K2026-01-05 · MULROY DENNIS sold $145.5K2026-01-05 · LOUMEAU ERIC J sold $129.0K2026-01-08 · MULROY DENNIS sold $112.4K2026-01-07 · Lizzul Paul F. sold $100.8K2026-01-08 · LOUMEAU ERIC J sold $98.8K2026-01-07 · LOUMEAU ERIC J sold $91.0K2026-01-07 · MULROY DENNIS sold $86.1K2026-01-07 · LOUMEAU ERIC J sold $84.9K2026-01-15 · Marquet Magda sold $83.5K2025-12-22 · Lizzul Paul F. sold $75.0K2026-03-27 · Faga Daniel sold $62.9K2026-03-27 · Faga Daniel sold $33.3K2026-03-30 · Schmid John P. sold $30.0K2026-03-27 · Faga Daniel sold $29.2K2026-03-27 · Faga Daniel sold $28.9K2026-01-07 · LOUMEAU ERIC J sold $23.6K2025-12-18 · LOUMEAU ERIC J sold $6.6K2026-03-27 · Faga Daniel sold $6.6K2026-10-01 · HOLLINGS C RENTON filed to sell $249.4K2026-07-13 · JOE ANTHONY WARE filed to sell $718.3K2026-06-30 · JOE ANTHONY WARE filed to sell $408.8K2026-06-29 · DENNIS MULROY filed to sell $601.2K2026-06-26 · DENNIS MULROY filed to sell $608.2K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ANAB: institutional holders (13F)

13F holdings, latest reported quarter
EcoR1 Capital, LLC
7,880,094 sh
$531.9M
BlackRock, Inc.
1,844,049 sh
$124.5M
TANG CAPITAL MANAGEMENT LLC
1,330,879 sh
$89.8M
STATE STREET CORP
1,286,194 sh
$86.8M
Palo Alto Investors LP
1,206,978 sh
$81.5M

Congress trades in ANAB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ANAB planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
HOLLINGS C RENTON
Filed 2026-10-01
$249.4K
JOE ANTHONY WARE
Filed 2026-07-13
$718.3K
JOE ANTHONY WARE
Filed 2026-06-30
$408.8K
DENNIS MULROY
Filed 2026-06-29
$601.2K
DENNIS MULROY
Filed 2026-06-26
$608.2K

ANAB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Biotechnology & Genome ETF
$6.5M position · as of 2026-07-31
2.3%
Victory RS Science & Technology Fund
$3.2M position · as of 2026-06-30
1.3%
Burney U.S. Equity Select ETF
$7.9M position · as of 2026-07-31
1.2%
Burney U.S. Factor Rotation ETF
$6.6M position · as of 2026-07-31
1.1%
Franklin Genomic Advancements ETF
$289.6K position · as of 2026-06-30
1.0%
Franklin Small Cap Enhanced ETF
$1.2M position · as of 2026-06-30
1.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
6
Phase 2
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.1M
$41.7M
$2.2M
+56%
n/a
2024
$13.6M
$9.2M
$3.9M
-57%
n/a
2023
$7.5M
-$1.7M
$2.3M
-31%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $249.4K sold by insiders over 180 days, 119 funds added last quarter, $249.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ANAB financials

Revenue growth
+157.0%
XBRL, annual
Net margin
-5.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$237.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+82.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$18.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
+60.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
effective tax rate -77%, not meaningful
Return on capital employed
+107.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
8.65x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
+1.2%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-062025-122024-122023-12
Revenuen/a$234.6M$91.3M$17.2M
Operating incomen/a$226.9M$66.2M-$164.4M
Net incomen/a-$13.2M-$145.2M-$163.6M
EPS (diluted)n/a-0.44-4.92-6.08
Operating cash flown/a$19.7M-$135.3M-$120.8M
Cash$133.8M$138.2M$23.1M$36.0M
Buybacksn/a$68.6M$456.0K$50.0M
SEC XBRL, fiscal years, as known on 2026-10-28

ANAB Stock Sonar score 5/7 axes

Find similar shapesCompare

ANAB ranks highest on profitability (98th percentile) and growth (88th), and lowest on insider conviction (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
98
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets+60.0% · 97 pct, sector of 691
  • Return on invested capitaleffective tax rate -77%, not meaningful
  • Return on capital employed+107.7% · 100 pct, sector of 576
Growth
88
Inputs
  • Revenue growth, YoY+157.0% · 88 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
0
Inputs
  • Net Form 4 buying (codes P and S), 180dno Form 4 purchase or sale (code P or S) in 180 days
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
75
Inputs
  • Funds adding, latest quarter119 · 75 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
34
Inputs
  • Short interest, % of float+25.6% · 7 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+8.7% · 60 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ANAB filings, in plain words

Are Anaptysbio insiders buying or selling ANAB?

In the 180 days to 2026-10-28, Anaptysbio insiders were net sellers, a net $249.4K across purchases and sales reported on Form 4, by 1 seller.

Are there planned insider sales of ANAB?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $249.4K of stock; the latest, by HOLLINGS C RENTON, was filed 2026-10-01.

Read the full summary

In the 180 days to 2026-10-28, Anaptysbio insiders were net sellers of ANAB, a net $249.4K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $249.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies